December 15, 2017 / 12:57 PM / a year ago

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

Dec 15 (Reuters) - Radius Health Inc:

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

* RADIUS HEALTH-EXPECTS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE TO ISSUE AN OPINION REGARDING MARKETING AUTHORISATION APPLICATION DURING H1 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below